Related Experiment Video
Updated: Jun 2, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Preventing hypoglycemia with novel technology and flexible therapy
1Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St. Louis, USA. jdunai@dom.wustl.edu
Missouri Medicine
|May 17, 2011
Summary
Diabetes is rising globally. New technologies and flexible treatments can reduce dangerous low blood sugar events (hypoglycemia) in patients with diabetes, especially those at higher risk.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Diabetes mellitus is a growing global health concern.
- Hypoglycemia, or low blood sugar, is a significant complication of diabetes treatment.
- Achieving optimal glycemic control is often hindered by the risk of hypoglycemia.
Observation:
- The increasing prevalence of diabetes necessitates strategies to mitigate treatment-related adverse events.
- Patients with specific risk factors are particularly vulnerable to hypoglycemia.
- Current treatment paradigms may not adequately address the challenge of frequent hypoglycemia.
Findings:
- New technological advancements in diabetes management show promise.
- Flexible treatment regimens can be tailored to individual patient needs.
- Targeted interventions for high-risk individuals may reduce hypoglycemia incidence.
Implications:
- Implementing advanced diabetes technologies can improve patient safety.
- Personalized treatment approaches are crucial for effective diabetes care.
- Reducing hypoglycemia frequency can enhance glycemic control and patient quality of life.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...